We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Alnylam Discontinues Revusiran Development

News   Oct 07, 2016

 
Alnylam Discontinues Revusiran Development
 
 
 

RELATED ARTICLES

Patent Issued for Osteoarthritis Gene Therapy Product

News

A potentially disease-modifying therapy for osteoarthritis has reached a key milestone now that a U.S. patent has been issued for FX201, a gene-therapy product candidate based on work led by Baylor College of Medicine researchers.

READ MORE

Stage Set for Uncovering Multiple Autoimmune Drug Targets

News

The identification of molecular signatures that reflect the pathology of lupus and arthritis provide new insights into tissue damage, and set the stage for uncovering potential drug target candidates.

READ MORE

Cargo Trafficked Across Bacteria on "Treadmills"

News

Bacteria have more in common with human cells than first thought; cargo is transited along treadmill-like structures by viruses in a process similar to what is found in our own cells. Understanding the process is fundamental to developing tailor-made phages for resistant infections.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Genomics Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE